Paradigm Asset Management CO LLC Regeneron Pharmaceuticals, Inc. Transaction History

Paradigm Asset Management CO LLC

$266 Million
Q3 2024

A detailed history of Paradigm Asset Management CO LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Asset Management CO LLC holds 1,000 shares of REGN stock, worth $712,330. This represents 0.4% of its overall portfolio holdings.

Number of Shares

1,000

Previous 1,000 -0.0%

Holding current value

$712,330

Previous $1.05 Million -0.0%

% of portfolio

0.4%

Previous 0.42%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $490,021 - $581,245	700 Added 233.33%	1,000 $718,000
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $705,890 - $766,390	-1,000 Reduced 76.92%	300 $216,000
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $164,505 - $221,652	300 Added 30.0%	1,300 $768,000
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $57,403 - $68,096	-100 Reduced 9.09%	1,000 $605,000
Q4 2020 Feb 12, 2021	BUY	$478.3 - $607.98 $47,830 - $60,798	100 Added 10.0%	1,100 $531,000
Q2 2020 Aug 11, 2020	BUY	$493.32 - $643.92 $493,320 - $643,920	1,000 New	1,000 $623,000
Q2 2019 Aug 08, 2019	SELL	$299.6 - $414.82 $44,940 - $62,223	-150 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$372.08 - $439.57 $18,604 - $21,978	-50 Reduced 25.0%	150 $0
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $33,582 - $40,304	-100 Reduced 33.33%	200 $74,000
Q4 2017 Feb 12, 2018	SELL	$358.63 - $469.95 $35,863 - $46,995	-100 Reduced 25.0%	300 $0
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $172,552 - $201,600	400	400 $0

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.4B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Asset Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Asset Management CO LLC with notifications on news.

Account

Paradigm Asset Management CO LLC Regeneron Pharmaceuticals, Inc. Transaction History